Skip to content

Spinal Cord Stimulation for Lower Extremity Function

Epidural Spinal Cord Stimulation for Lower Extremity Motor Function in Spinal Cord Injury

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06438991
Enrollment
10
Registered
2024-06-03
Start date
2024-07-31
Completion date
2028-06-30
Last updated
2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Cord Injury

Keywords

epidural spinal cord stimulation

Brief summary

This prospective clinical study will investigate the ability of different spine imaging characteristics to predict ambulation recovery responsiveness using epidural spinal cord stimulator (SCS) in patients with chronic incomplete spinal cord injury (SCI). Epidural spinal cord stimulation below the level of injury can restore previously lost lower extremity voluntary motor function for some patients. The goal of this study is to establish whether spine imaging can be utilized as a biomarker to predict which patients will respond to spinal cord stimulation.

Detailed description

Ten patients with chronic spinal cord injury who are scheduled to receive a spinal cord stimulator for refractory chronic pain will be recruited throughout the Mass General Brigham health system. At baseline, participants will undergo a neurologic strength exam, Magnetic Resonance Imaging (MRI) of the spine and brain, electromyography (EMG) of the lower extremities, and will complete a battery of pain, motor function and quality of life questionnaires. Phase 1: The SCS Optimization phase consists of weekly research visits during the first month post-SCS implant. Settings of the spinal cord stimulator parameters will be modified for activation and optimal voluntary control of lower extremity muscles. Phase 2: The Individualized Neurorehabilitation phase consists of 4 weekly visits for a 5-month period. Participants will undergo neurorehabilitation with the stimulation settings turned on for motor control. Neurorehabilitation will be individualized and will progressively increase participants' physical activity, including assisted/independent standing, stepping and ambulation within safe limits. Participants will undergo monthly muscle strength and surface EMG testing. At the end of each research visit or neurorehabilitation session, SCS settings will be adjusted to the original pain management parameters. At the 6-month follow up participants will undergo a neurologic strength exam, MRI of the spine and brain, EMG of the lower extremities and a battery of questionnaires. After the last follow up visit, participants will have the opportunity to continue a long-term follow up or exit the study. SCS parameters will be adjusted to the pain management settings.

Interventions

OTHERAdjustment of spinal cord stimulation parameters for voluntary motor control

All patients will receive a spinal cord stimulator and undergo adjustment of stimulation parameters for optimal voluntary lower extremity motor control during research visits. Muscle strength will be assessed with the stimulation turned on and off.

Sponsors

Brigham and Women's Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Intervention model description

All subjects will receive a spinal cord stimulator. Muscle strength will be assessed with the stimulation turned on and off. Parameters for motor function will be assessed with the stimulation turned on and off.

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Age \>18 years * Provides informed consent * Eligible for and undergoes SCS implant for chronic low back or leg pain refractory to first-line therapy * Stable SCI secondary to a single insult * C6-T10 level of injury * SCI has occurred \>12 months prior to enrollment * Chronic low back pain refractory to first-line therapy * Current AIS grade B-C, with spared sensation * Willingness and ability to adhere to the protocol

Exclusion criteria

* History or diagnosis of Central Nervous System malignancy * Diagnosis that is a contraindication to SCS implantation or surgery * Diagnosis that precludes the subject from full participation in physical therapy * Known osteopenia/osteoporosis * Impairment in post-operative recovery per clinical evaluation by the principal investigator * Inability to participate in the protocol, including but not limited to all study visits and assessments

Design outcomes

Primary

MeasureTime frameDescription
Incidence of treatment-related adverse events0-6 months after baselineThe primary endpoint of this study is the safety of stimulation parameters for motor function assessed with the number of adverse events for the duration of the study. Relatedness of adverse events to treatment is determined by the principal investigator.

Secondary

MeasureTime frameDescription
Neuroimaging volumetric measures0-6 months after baselineAssessment of the functional integrity of corticospinal tracts with spine and brain Magnetic Resonance Imaging (MRI) will be performed at baseline and at the last follow up. MRI volumetric measures are quantified in mm\^2.
Voluntary Motor Function0-6 months after baselineFunctional change assessed with the total score on the American Spinal Injury Association Impairment Scale (AIS) of each participant before spinal cord stimulation (SCS) and after SCS augmented with neurorehabilitation therapy. The AIS scale ranges from A (no sensory or motor function is preserved in sacral segments of S4-S5) to E (sensation and motor testing are normal in all segments), with A representing the worst outcome and E representing the best outcome.
Optimized stimulation amplitude for voluntary motor function1-6 months after baselineStimulation amplitude required for voluntary motor function measured in mA (miliAmperes) when supine, assisted/independent standing, stepping, walking.
Muscle Strength1-6 months after baselineThe ability to restore previously lost voluntary motor function of the lower extremity will be measured with the Medical Research Council (MRC) grade and compared to baseline. MRC grades range from 0 (no visible muscle contraction) to 5 (normal muscle strength against full resistance). A higher grade indicates a better outcome.
Optimized stimulation pulse width for voluntary motor function1-6 months after baselineStimulation pulse width required for voluntary motor function measured in microseconds when supine, assisted/independent standing, stepping, walking.
Locomotive ability1-6 months after baselineAbility to stand, step, or walk either assisted or unassisted assessed with the Walking Index for Spinal Cord Injury II (WISCI II) scale. The WISCI II scale ranges from minimum score of 0 (unable to stand) to maximum score of 20 (ambulates with no devices, brace or assistance). A higher score represents a better outcome.
Serious adverse events1-6 months after baselineSerious adverse events related to the post-SCS implant neurorehabilitation therapy.
Optimized stimulation frequency for voluntary motor function1-6 months after baselineStimulation frequency required for voluntary motor function measured in Hz (Hertz) when supine, assisted/independent standing, stepping, walking.

Contacts

Primary ContactJoshua I. Chalif, MD, PhD
jchalif@bwh.harvard.edu617-525-7378
Backup ContactBenjamin R Johnston, MD, PhD
bjohnston2@mgb.org617-525-7378

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026